Table 2.
Regions activated for No-Go correct rejects compared to implicit baseline in participants with or without a family history of alcoholism and after either placebo or memantine
| Region (BA) | Left hemisphere |
FHP vs. FHN (placebo)a |
FHP—effect of memantineb |
Right hemisphere |
FHP vs. FHN (placebo)a |
FHN—effect of memantineb |
|---|---|---|---|---|---|---|
| Superior frontal gyrus (10) | −30, 48, 24 | 33, 51, 27 | ||||
| Supplementary motor area (6) | −15, 9, 69 | 9, 6, 69 | ||||
| Middle frontal gyrus (6/8) | −45, 3, 51 | 33, 3, 54 | ||||
| Inferior frontal gyrus (9/47) | −60, 6, 24 | 48, 18, −3 | ||||
| Anterior cingulate (32) | −15, 33, 21 | ↓ | 12, 30,24 | ↑ | ||
| Precentral gyrus (6) | −42, 0, 54 | 48, 6, 45 | ||||
| Insula | −39, 12, −6 | 39, 18, 0 | ||||
| Caudate | −6, 15, 12 | ↓ | − | |||
| Putamen | −24, −63, 51 | 12, −69, 51 | ||||
| Thalamus | −12, −18, 6 | 15, −12, 9 | ||||
| Pons | − | 9, −30, −39 | ||||
| Parahippocampal gyrus | − | 21, −33, −3 | ||||
| Posterior cingulate (23) | −3, −30, 24 | 9, −33, 27 | ||||
| Inferior parietal lobule (40) | −42, −39,48 | ↑ | 57, −39, 42 | |||
| Superior temporal gyrus (38) | −51, 12, −9 | 51, 18, −9 | ||||
| Middle temporal gyrus (37) | −51, −57, 3 | 57, −57, 0 | ||||
| Middle occipital gyrus (18) | −33, −96, −6 | 48, −75, −9 | ||||
| Inferior occipital gyrus (18) | −39, −90, −9 | 30, −96, −9 | ||||
| Fusiform gyrus (39) | −39, −66, −18 | 42, −51, −21 | ||||
| Tonsil | −39, −48, −42 | 33, −57, −42 | ||||
| Vermis | 3, −78, −24 | |||||
| Declive | −36, −60, −27 | 36, −60, −27 | ||||
| Cerebellum crus 1 | −30, −60, −33 | 36, −54, −33 | ↓ | |||
| Cerebellum crus 2 | −33, −63, −39 | 42, −48, −39 |
Regions activated for No-Go correct rejects >baseline across groups during placebo. Only variables showing significant experimental effects are shown, thus FHN effect of memantine for the left hemisphere and FHP effect of memantine right hemisphere are not shown
Regions showing differences between groups during placebo. An upward arrow represents greater activity for FHP vs. FHN and a downward arrow represents a reduction in activity for FHP vs. FHN
Regions showing changes in activity for memantine vs. placebo. A downward arrow represents a reduction in activity during memantine challenge vs. placebo, an upward arrow represents an increased in activity during memantine challenge vs. placebo